Lilly strikes $1.9bn kidney disease alliance with Ascidian
In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.
ASCO26: Celcuity punished as trial disappoints investors
Celcuity is still confident it has a winner with its breast cancer treatment, gedatolisib, but investors seem less convinced by new VIKTORIA-1 data.
FDA prior knowledge guide seeks to speed cell, gene therapy
The FDA has laid out a framework to use 'prior knowledge' on manufacturing, non-clinical, and clinical data to support cell and gene therapy filings.
ASCO26: In vivo CAR-Ts in the spotlight
Data at ASCO on in vivo CAR-Ts from Kelonia and Legend add to the excitement about the emerging therapy class in both blood cancers and solid tumours.
ASCO26: After negative adcomm, AZ builds case for oral SERD
AstraZeneca showcases new data from the SERENA-6 data of camizestrant in breast cancer that it hopes will get FDA's review of the drug back on track.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Inizio Launches Intelligent Congress to Turn Event Investmen...
Inizio, the leading global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress
17th World ADC San Diego | October 12-15, 2026
The World’s Premier Forum to Advance Differentiated ADCs to Redefine Early-Line Oncology Patient Outcomes
6th Rare & Genetic Kidney Disease Drug Development Summit
The 6th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston on August 18–20, 2026, bringing together global leaders advanc
Navigating Change: Key Industry Insights at PHARMAP 2026
PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor
Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...
EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery